Thrombosis Research
Volume 121, Issue 3 , Pages 289-291 , 2007

Measuring soluble CD40 ligand:interleukin-10 ratio as a prognostic marker in acute myocardial infarction: Yet another prognostic biomarker?

Received 30 April 2007 ,Revised 30 April 2007 ,Accepted 5 May 2007.

References 

  1. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–2850
  2. Ziakas A, Gavrilidis S, Giannoglou G, Souliou E, Gemitzis K, Kalampalika D, et al. In-hospital and long term prognostic value of fibrinogen, CRP, and IL-6 levels in patients with acute myocardial infarction treated with thrombolysis. Angiology. 2006;57:283–293
  3. Baustista LE, Vera LM, Arenas IA, Gamarra G. Idependent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149–154
  4. Barani J, Nilsson JA, Mattiasson I, Lindblad B, Gottsater A. Inflammatory mediators are associated with 1-year mortality in critical limb ischaemia. J Vasc Surg. 2005;42:75–80
  5. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. Apr 2007;38(4):1229–1237
  6. Blake GJ, Rider PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(4 Suppl S):37S–42S
  7. Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis. Atherosclerosis. 1998;137:89–95[Suppl: S]
  8. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96:2304–2310
  9. Lindmark E, Tenno T, Chen J, Siegbahn A. IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood. Br J Haematol. 1998;102:597–604
  10. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Marelli D, Moriguchi J, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002;90:1064–1071
  11. Heeschen C, Dimmeler S, Hamm WC, Fichtlscherer S, Boersma E, Simoons LM, et al. Serum levels of the anti-inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:2109–2119
  12. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez JM, Kaski CJ. Soluble CD40 ligand: Interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res. 2007;121:293–299(this issue)
  13. Boos CJ, Lip GYH. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension?. J Hum Hypertens. 2005;19:511–513
  14. Rifai N, Ridker PM. High sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403–411
  15. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentration in healthy human subjects. Clin Chem. 2001;47:426–430
  16. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Eng J Med. 2001;344:1959–1965
  17. Celik T, Iyisoy A, Kursaklioglu H, Turhan H, Kilic S, Kose S, et al. The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron Artery Dis. 2005;16:293–299

PII: S0049-3848(07)00216-2

doi: 10.1016/j.thromres.2007.05.011

Thrombosis Research
Volume 121, Issue 3 , Pages 289-291 , 2007

Article Tools